ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1837

Clinical Outcomes in Lupus Nephritis by Renal Response Status: A Retrospective Analysis of the Hopkins Lupus Cohort

Michelle Petri1, Qinggong Fu2, Yulia Green3, Anuradha Madan4, Daniel Goldman5 and Selin Cooper-Blenkinsopp6, 1Johns Hopkins University School of Medicine, Baltimore, 2GlaxoSmithKline, Upper Providence, 3GlaxoSmithKline, Uxbridge, 4GlaxoSmithKline, Collegeville, 5Johns Hopkins University School of Medicine, Timonium, MD, 6GlaxoSmithKline, Stevenage, United Kingdom

Meeting: ACR Convergence 2020

Keywords: , ,

Session Information

Date: Monday, November 9, 2020

Title: SLE – Treatment Poster II

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: A retrospective analysis of the Hopkins Lupus Cohort (a prospective, longitudinal study of patients [pts] with systemic lupus erythematosus) reported that renal response (complete/partial/none) at 24 months post-diagnosis of lupus nephritis (LN) predicts long-term renal survival.1 Here, we compare long-term renal survival and chronic renal insufficiency-free survival in pts with and without a renal response (RR) to standard LN therapy, as defined by primary endpoint in the Phase 3 BLISS-LN study (GSK Study BEL114054; NCT01639339).

Methods: This retrospective analysis (GSK Study 213039) of the Hopkins Lupus Cohort included pts with biopsy-proven class III, IV, or V LN. Endpoints were: long-term renal survival (no end-stage renal disease [ESRD] and/or mortality) and long-term chronic renal insufficiency-free survival by RR status at 24 months post-biopsy, both assessed by Kaplan−Meier plots with log-rank test and Cox proportional hazards regression.

Results: 173 pts with LN were included; 91.3% were female and mean (SD) age at biopsy was 36.2 (11.8) years. At 24 months post-biopsy, 114 (65.9%) pts achieved RR. Pts with RR at 24 months were less likely to experience an ESRD/mortality event and chronic renal insufficiency (Figure), even after adjusting for covariates (HR [95% CI] 0.33 [0.13, 0.87], p=0.0255; and HR [95% CI] 0.26 [0.14, 0.47], p< 0.0001, respectively).

Conclusion: Achieving BLISS-LN primary endpoint defined RR at 24 months post-biopsy is associated with long-term renal survival and chronic renal insufficiency-free survival in pts with LN.

Prior presentation: Submitted to ASN 2020. If accepted (notifications due August 7), to be presented at Kidney Week 2020 from October 20, 2020 – October 25, 2020 and published in the ASN Abstract Supplement PDF, which will be posted online by October 9, 2020.

Reference: 1. Davidson JE, et al. J Rheumatol 2018;45(5):671–7.

Disclosure: M. Petri, AbbVie, 5, Amgen, 5, AstraZeneca, 2, 5, BMS, 5, Decision Resources, 5, GSK, 2, 5, INOVA, 5, IQVIA, 5, Janssen, 5, Eli Lilly, 2, 5, Merck EMD Serono, 5, Sanofi Japan, 5, Thermofisher, 5, UCB, 5, Exagen, 2; Q. Fu, GSK, 3, 4; Y. Green, GSK, 1, 2, 3; A. Madan, GSK, 3, 4; D. Goldman, None; S. Cooper-Blenkinsopp, GSK, 3, 4.

To cite this abstract in AMA style:

Petri M, Fu Q, Green Y, Madan A, Goldman D, Cooper-Blenkinsopp S. Clinical Outcomes in Lupus Nephritis by Renal Response Status: A Retrospective Analysis of the Hopkins Lupus Cohort [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/clinical-outcomes-in-lupus-nephritis-by-renal-response-status-a-retrospective-analysis-of-the-hopkins-lupus-cohort/. Accessed .

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-outcomes-in-lupus-nephritis-by-renal-response-status-a-retrospective-analysis-of-the-hopkins-lupus-cohort/